CervoMed Inc. Files Routine 8-K, Confirms Corporate Details

TL;DR

**CervoMed Inc. filed a routine 8-K, updating basic company info and confirming its NASDAQ listing.**

AI Summary

CervoMed Inc. filed an 8-K on January 4, 2024, primarily to disclose its current corporate information, including its business address at 20 Park Plaza, Suite 424, Boston, Massachusetts 02216, and its NASDAQ Capital Market listing under the trading symbol CRVO. This filing is a routine update, indicating no major new events but confirming the company's operational details. For investors, this matters because it provides current, verified contact and listing information, which is essential for due diligence and understanding the company's basic public profile.

Why It Matters

This filing provides updated administrative and contact information for CervoMed Inc., ensuring transparency and current public records for investors. It confirms the company's listing on the NASDAQ Capital Market under the ticker CRVO.

Risk Assessment

Risk Level: low — This 8-K is a standard administrative filing and does not contain information that would significantly alter the company's risk profile.

Analyst Insight

A smart investor would note this filing as a routine administrative update, confirming current company details. It doesn't signal any immediate investment action but reinforces the importance of checking current filings for accurate corporate information.

Key Numbers

• 001-37942 — Commission File Number (SEC file number for CervoMed Inc.)
• 30-0645032 — I.R.S. Employer Identification No. (IRS number for CervoMed Inc.)
• (617) 744-4400 — Business Phone Number (contact number for CervoMed Inc.)
• 2024-01-04 — Date of Report (date the earliest event reported in the 8-K occurred)

Key Players & Entities

• CervoMed Inc. (company) — the registrant filing the 8-K
• NASDAQ Capital Market (company) — the exchange where CervoMed Inc.'s common stock is registered
• CRVO (other) — CervoMed Inc.'s trading symbol
• Boston, Massachusetts (other) — location of CervoMed Inc.'s principal executive offices
• Delaware (other) — state of incorporation for CervoMed Inc.

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value   CRVO   NAS

Filing Documents

• crvo20240104_8k.htm (8-K) — 31KB
• 0001437749-24-000563.txt ( ) — 160KB
• crvo-20240104.xsd (EX-101.SCH) — 3KB
• crvo-20240104_def.xml (EX-101.DEF) — 11KB
• crvo-20240104_lab.xml (EX-101.LAB) — 15KB
• crvo-20240104_pre.xml (EX-101.PRE) — 11KB
• crvo20240104_8k_htm.xml (XML) — 2KB

01

Item 7.01. Regulation FD Disclosure   Corporate Presentation   Certain information concerning the business, clinical studies, development plans, financial position and related matters of CervoMed Inc. (the "Company" or "us") has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.   The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure.   The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18 of the Exchange Act unless we specifically incorporate it by reference in a document filed under the Exchange Act, nor shall it be deemed incorporated by reference in any fil

Financial Statements and Exhibits

Financial Statements and Exhibits   (d) Exhibits   Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: January 4, 2024 CervoMed Inc. By: /s/  William Elder Name: William Elder Title: General Counsel    

View Full Filing

View this 8-K filing on SEC EDGAR